Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid
- 12 November 2009
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 119 (3) , 613-620
Abstract
Tamoxifen reduces primary breast cancer incidence, yet causes serious side effects. To date, few women with increased breast cancer risk have elected to use tamoxifen for chemoprevention. The objective of the study was to determine women’s knowledge of and attitudes toward tamoxifen following exposure to a tailored decision aid (DA). A total of 632 women with a 5-year risk of breast cancer ≥1.66% (Mean = 2.56, range = 1.7–17.3) were recruited from two healthcare organizations. Participants viewed an online DA that informed them about their 5-year risk of breast cancer and presented individually tailored content depicting the risks/benefits of tamoxifen prophylaxis. Outcome measures included behavioral intentions (to seek additional information about tamoxifen, to talk to a physician about tamoxifen, and to take tamoxifen); knowledge; and perceived risks and benefits of tamoxifen. After viewing the DA, 29% of participants said they intended to seek more information or talk to their doctor about tamoxifen, and only 6% believed they would take tamoxifen. Knowledge was considerable, with 63% of women answering at least 5 of 6 knowledge questions correctly. Participants were concerned about the risks of tamoxifen, and many believed that the benefits of tamoxifen did not outweigh the risks. This study is the largest to date to test women’s preferences for taking tamoxifen and one of the largest to have tested the impact of a tailored DA. After viewing the DA, women demonstrated good understanding of tamoxifen’s risks and benefits, but most were not interested in taking tamoxifen for breast cancer chemoprevention.Keywords
This publication has 13 references indexed in Scilit:
- Web Survey Methods: IntroductionPublic Opinion Quarterly, 2008
- Communicating side effect risks in a tamoxifen prophylaxis decision aid: The debiasing influence of pictographsPatient Education and Counseling, 2008
- “Why take it if you don’t have anything?” breast cancer risk perceptions and prevention choices at a public hospitalJournal of General Internal Medicine, 2006
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutationFamilial Cancer, 2005
- Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reductionCancer, 2005
- Decision-Making About Tamoxifen in Women at High Risk for Breast Cancer: Clinical and Psychological FactorsJournal of Clinical Oncology, 2004
- Development and evaluation of a breast cancer prevention decision aid for higher‐risk womenHealth Expectations, 2003
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI: Journal of the National Cancer Institute, 1989